Start Codon

TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD).

Awen Oncology is a pharmaceuticals start-up that is drugging developmentally-silent oncogenic drivers.

NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.

Coding.bio provides AI for cell therapies through automation and computation. They work at the intersection of computation, synthetic biology, and cell therapy. They also provide curative therapeutics for patients.

Enhanc3D Genomics is a functional genomics company that focuses on understanding the three-dimensional organization of DNA and its implications for health and disease. The company has developed the GenLink3D platform, which facilitates the analysis of genetic variations and gene function by providing high-resolution profiles of genome folding. This technology allows researchers to examine the effects of mutations on distant genes and their roles in disease progression. By offering insights into gene interactions and enhancer activity, Enhanc3D Genomics aims to support the advancement of novel drug development in areas with significant unmet medical needs.

Spirea Ltd. is a healthcare technology company based in Harrogate, United Kingdom, that specializes in developing antibody drug conjugates (ADCs) for cancer treatment. Founded in 2015, Spirea has created a smart polymer platform designed for the controlled delivery of drug combinations, thereby maximizing the clinical efficacy of therapies. The company's innovative approach to ADCs allows for a greater amount of drug payload to be specifically targeted to tumor cells, resulting in enhanced therapeutic effects while significantly minimizing side effects. This development enables healthcare providers to offer well-tolerated treatment options for a variety of cancers, ultimately aiming to improve the quality of life for patients.

Semarion is a spin-out from the Cavendish Laboratory at the University of Cambridge, specializing in drug discovery and cell microcarrier technology. The company aims to enhance the process of drug screening by utilizing innovative materials and techniques from the microchip industry combined with cell biology. Its platform features ultra-miniaturized, magnetically steerable microcarriers designed to support small colonies of cells, which facilitates advanced assaying workflows and new experimental approaches. This technology is particularly focused on identifying GPCR-targeting oncology drugs, addressing significant gaps in medical needs and accelerating the pace of drug development.